What is Craif?
Craif operates at the intersection of biotechnology and preventative medicine, specializing in the analysis of exosomes to optimize treatment protocols for a wide range of diseases. The company's core value proposition lies in its ability to provide a painless, highly accurate diagnostic alternative to traditional biopsy methods. By establishing a scalable platform for early detection, Craif aims to fundamentally shift the healthcare paradigm toward proactive health management, ensuring that patients can maintain wellness throughout their lives. Its market position is bolstered by a commitment to rigorous research and development, enabling the firm to address critical gaps in current diagnostic infrastructure.
The company's growth trajectory has been marked by consistent backing from both institutional financial entities and impact-focused investment groups. This strategic alignment allows Craif to bridge the gap between laboratory innovation and commercial-scale healthcare delivery, effectively navigating the complexities of the global diagnostic market.
How much funding has Craif raised?
Craif has raised a total of $67.8M across 4 funding rounds:
Seed
$242K
Series C
$6.3M
Series C
$28.3M
Series D
$33M
Seed (2019): $242K, investors not publicly disclosed
Series C (2024): $6.3M, investors not publicly disclosed
Series C (2025): $28.3M supported by Unreasonable Group and Aozora Bank
Series D (2026): $33M featuring 株）タウンズ, Unreasonable Group, and Granite Asia
Key Investors in Craif
Granite Asia
Granite Asia is a leading multi-asset investment platform managing significant capital, focusing on health innovation and consumer growth across the Asian market.
Unreasonable Group
Unreasonable Group supports entrepreneurs solving global challenges through accelerator programs and private equity, with a specific focus on reimagining the future of healthcare.
Aozora Bank
Aozora Bank is a long-standing Japanese financial institution providing comprehensive banking products and services to support corporate growth and development.
What's next for Craif?
With the successful closure of this latest financing round, Craif is well-positioned to accelerate its clinical validation efforts and expand its diagnostic footprint. The capital will likely be deployed to enhance the sensitivity of its exosome collection technology and to scale operations to meet the growing demand for non-invasive screening tools. As the company matures, the focus will shift toward securing regulatory approvals in key international markets and forging partnerships with major healthcare providers. By maintaining its focus on high-impact medical outcomes, Craif is poised to redefine the standards of early disease detection, ultimately driving long-term value for stakeholders and patients alike.
See full Craif company page
